Biologos will be participating in the Limb Preservation Foundation’s annual symposium. We look forward to connecting with clients at the event that highlights the advancement of limb preservation awareness and care.
Cell and Gene Therapies (CGTs) represent one of the most transformative innovations in modern medicine, offering curative potential for previously untreatable diseases. Today, the CGT market is valued at $15.48 billion, and with breakthrough approvals, increased investment and a rapidly expanding pipeline, it is projected to grow to $28.9 billion by 2029 [1].
The biopharmaceutical manufacturing landscape is evolving rapidly, driven by the rise of personalized therapies, technological advancements, and increasingly stringent regulatory requirements. While these innovations present exciting opportunities, they also introduce new complexities in scaling production, maintaining quality and compliance, and managing rising costs and logistics.